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CObjectives: The aim of this study was to investigate the relationship be-
tween symptom severity, cost, and impairment in women with moder-
ate/severe premenstrual syndrome (PMS) or premenstrual dysphoric dis-
order (PMDD) in a Latin American setting. Methods: A model was
constructed based on analysis of an observational dataset. Data were in-
cluded from four Latin American countries. Responder-level data were
analysed according to four categories of symptom severity: Category 1
comprised Daily Record of Severity of Problems score 21 to 41.9, Category
2 scorewas 42 to 62.9, Category 3 scorewas 63 to 83.9, and Category 4was
a score of 84 or higher. Burden was estimated in terms of impact on job
andactivitiesusing themodifiedworkproductivityand impairmentques-
tionnaire and affect on quality of life using the SF-12 questionnaire. Costs
were estimated in Brazilian reals from a Brazilian private health care and
societal perspective. The outputs of the analysis were estimates of bur-
den,meanannual cost andaffect onquality of life (asmeasuredbyquality








oi:10.1016/j.jval.2011.05.008utcomes were generated through nonparametric bootstrapping.
esults: Analysis suggests a significant cost burden associated with
oderate/severe PMS and PMDD with mean per patient annual costs
stimated at 1618 BRL (95% confidence interval 957–2,481). Although
he relationship between cost, quality of life, and severity was not
lear, analysis showed a consistent relationship between disease se-
erity and measures of disease burden (job and daily activity). Burden
n activities increased with disease severity. Conclusions: Our analy-
is, conducted from a Latin American perspective, suggests a signifi-
ant burden and an increasing impairment associated with moderate/
evere PMS and PMDD.
eywords: burden, daily record of severity of problems, premenstrual
ysphoric disorder, premenstrual syndrome.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Premenstrual dysphoric disorder (PMDD) is a severe form of pre-
menstrual syndrome (PMS). Key features include depressedmood,
anxiety, affective liability, persistent anger or irritability, and
change in appetite or sleep. By Diagnostic Statistical Manual, 4th
edition, definition, in women with PMDD symptoms are severe
enough to markedly affect usual daily activities. More than 80% of
women of reproductive age may experience some emotional
and/or physical premenstrual symptoms [1-3] and approximately
3% to 8% of menstruating women have symptoms that are severe
enough to meet the specific diagnostic criteria for PMDD [4,5]. Ex-
pert review of country-specific data suggests that the prevalence
of PMS/PMDD may be higher in Latin American countries than in
North American or European cohorts [6].
PMDD and moderate/severe PMS are associated with signif-
icant impairment as measured by a number of scales [7,8]. How-
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ublished by Elsevier Inc.ever, there are only a limited number of studies available that
attempt to quantify the influence of these impairments [9,10].
To the author’s knowledge, no studies have been conducted
from a Latin American perspective. In the absence of such data,
a comprehensive awareness of the impact of PMDD is lacking.
Within Latin America, PMDD is not fully accepted as a discrete
disease entity. Providing more evidence on the burden of PMDD
is likely to increase the awareness of PMDD and more clearly
define the disease.
A multicountry observational study was recently conducted
in women to assess the impact of pre-menstrual symptoms (see
Box 1 in Supplemental Material found at doi:10.1016/j.jval.
2011.05.008). The impact was measured through assessment of
direct and indirect outcomes via the modified work productivity
and impairment questionnaire (m-WPAI) and the impact on
quality of life through use of the SF-12 questionnaire. The study
has generated new information about resource use and quality
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S94 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) S 9 3 – S 9 5of life among women with PMS [11]. This article reports an anal-
ysis of these data designed to quantify the burden associated
with PMDD and moderate/severe PMS in women from a Latin
American subset of the dataset.
Methods
The aim of our study was to investigate the relationship between
symptoms, burden, and impairment in women with moderate/
severe PMS or PMDD, based on the findings of amulticenter obser-
vational study (the IMPACT study) and assignment of country-
specific cost data. The IMPACT study [11] reported symptom
severity, measured by the Daily Record of Severity of Problems
(DRSP) form, alongside impairment measured by amodifiedWPAI
scale, resource use, productivity, and quality of life. TheDRSP is an
acceptedmeasure of the severity of symptoms and impairment at
various phases of the menstrual cycle [12] (see Box 2 in Supple-
mental Materials found at; doi:10.1016/j.jval.2011.05.008). The
WPAI is a validated scale formeasurement of the effects of disease
on daily living activities and includes assessment of affect on pro-
ductivity. Versions of the scale have been validated in a Latin
American setting [13]. The original WPAI was modified to include
additional questions related to resource use.
In our analysis, impairment (as measured by the m-WPAI), an-
nual direct and indirect costs (estimated from reported resource
use and lost productivity), and quality-adjusted life years (QALYs)
(estimated from reported quality of life) were estimated according
to symptom severity for a subset of women included in the obser-
vational study. The observational study was pan-global with data
collected from women in 19 countries. Our analysis focused on
Latin America, and was limited to consideration of a subset of the
cohort of women from the four Latin American countries included
in the observational study (Brazil, Venezuela, Colombia, and Mex-
ico). We additionally considered only those women experiencing
moderate/severe PMS or PMDD. Data were pooled to increase the
power of the analysis and retain the statistical integrity of the
dataset. We explored the health statistics of the four included
countries to determine if they constituted an economically similar
group suitable for pooled analysis [14]. The aim was to develop a
dataset thatmight serve as a proxy for individual country analyses
in a Latin American setting.
The country perspective selected was that of Brazil and the
cost analysis was conducted from a Brazilian perspective. A soci-
etal perspective based on private health care costs was chosen.
The Brazilian health care system is a two-tier system with a na-
tional health system (Sistema Único de Saúde) as well as a supple-
mentary private medical system funded by private funds or
through work insurance schemes. The burden of disease calcu-
lated is most relevant to those women who used the private sys-
tem in that these women would be most likely to seek treatment
for PMDD. We therefore analyzed the burden of moderate to se-
vere PMS and PMDD from a private health perspective, including
the costs to the government from lost productivity.
Severity was defined by DRSP total luteal score, and costs and
QALYs were reported by the defined categories of severity. The
approach to categorization followed previously reported analyses
[15]. Five severity categories were initially defined on the basis of
previous analysis. Initial review of the data indicated very limited
numbers in the top two severity categories; these categories were
therefore combined to improve the sample size of the analysis.
The reported analyses are based on four categories: Category 1
comprised women with DRSP scores 21 to 41.9, Category 2 was
made up of womenwith scores 42 to 62.9, Category 3 wasmade up
of women with scores of 63 to 83.9, Category 4 included women
with scores of 84 or more. Category 1 includes those women with
minimal symptoms; Category 4 includes women at the most se-vere end of the symptom score spectrum. These women are ex-
pected to show significant impairment.
To quantify the costs, available per cycle data on lost produc-
tivity and medical resource use were extracted from the dataset
for each responder and unit costs were applied. These data were
then extrapolated to estimate an annual expected cost. We con-
ducted this analysis assuming a Brazilian perspective. The num-
ber of hours of lost productivity as reported in the m-WPAI data
were multiplied by an hourly wage for Brazil to estimate the total
cost of lost productivity per respondent per cycle andwere extrap-
olated to estimate annual costs. Costs for respondents not in em-
ployment (and therefore reporting lost productivity relating to
household chores) were calculated in the same manner, as the
cost of their time is represented by the opportunity cost, which is
to be in paid employment (following the human capital approach).
We obtained a wage of 7.23 BRL per hour for female manual work-
ers in the private sector [16].
Data related to reduced productivity (i.e., presenteeism) and
affect on daily living activities were also analysed by DRSP cate-
gory. Data were analysed according to the degree of affect on
work or daily living activities reported in the m-WPAI. Re-
sponses were collapsed into two categories, moderate/severe
affect, or mild/not relevant affect. To better understand the
study findings, reported treatment use was also estimated and
analysed according to country.
Results
Table 1 (Table 1 in Supplemental Materials found at doi:10.1016/
j.jval.2011.05.008) shows expenditure on health by country using a
number of indicators from the World Health Organization data-
base [14]. Because our analysis relies on having a sufficient sample
size to assess effects of disease severity by category, we chose to
include all countries in the analysis despite some discrepancies in
the similarity of their health expenditures (the implications of this
are reviewed in the Discussion).
The analysis dataset comprised a total of 292 women classified
as having moderate/severe PMS or PMDD. Data on quality of life
were reported for a subset of these women and 63 women are
included in the analysis of utility outcomes. Women were as-
signed to categories according to their DRSP total luteal symptom
score.
Unit costs (Table 2 in Supplemental Materials at doi:10.1016/
j.jval.2011.05.008) were applied to resource estimates to estimate
costs. Mean per cycle values for lost productivity and medical re-
source use were calculated for each DRSP category and extrapo-
lated to estimate the expected mean annual cost and utility influ-
ence as measured by QALY (Table 3 in Supplemental Materials
found at: doi:10.1016/j.jval.2011.05.008). Confidence intervals (CIs)
are reported to address the issue of uncertainty. Themean annual
cost perwomanwithmoderate/severe PMSor PMDD (independent
of severity) was estimated at 1618 BRL (95% CI 957 BRL–2481 BRL).
The level of influence on work and daily living activities was
estimated. Figure 1 (in Supplemental Materials found at doi:
10.1016/j.jval.2011.05.008) shows the proportion of women who
rated the burden of their condition on job activities as “not rele-
vant/mild” or “moderate/severe” by DRSP category. Figure 2 (in
Supplemental Materials at doi:10.1016/j.jval.2011.05.008) shows
the proportion of womenwho rated the burden on daily living activ-
ities as “not relevant/mild” or “moderate/severe” by DRSP category.
The profile of individual country resource use was explored. Fig-
ure 3 (in Supplemental Materials found at: doi:10.1016/j.jval.2011.05.
008) reports the percentage of women who reported treatment use
across all resource categories.
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Categorical analysis of the observational data according to DRSP
score found that work and daily activity impairment increased
with DRSP severity. Our analysis of the data suggests a significant
cost burden associated with moderate/severe PMS and PMDD al-
though the relationship between severity and cost is not clear.
In this example, costs are estimated fromaBrazilian societal per-
spective. Analysis of the individual country resource use data sug-
gested differences in resource profiles.Wewould suggest that differ-
ence in resource use may in part be explained by the different
distribution of disease severity across the individual country data-
sets (Figure 4 in Supplemental Materials found at: doi:10.1016/j.jval.
2011.05.008). For example, Brazil has a much lower proportion of
women in the lowest DRSP category (13% compared to 34%, 29%,
and 22% for Colombia, Venezuela, and Mexico, respectively),
whereas the Venezuelan and Mexican cohorts had proportion-
ally smaller numbers of women in the highest DRSP category.
This is in itself an interesting finding that may suggest a differ-
ence in perception of severity of symptoms across the Latin Amer-
ican countries included in the analysis. Further investigation of
this is beyond the scope of the current article.
Analysis of the costs associated withmedical resource use and
lost productivity and the effects on quality of life did not show the
expected relationship with disease severity. Our analysis showed
a relationship between disease severity and measures of disease
burden (e.g., job burden, activity burden, and number of treat-
ments used). This analysis showed that, as expected, the propor-
tion of women who experience burden on their activities/use of
treatments increases with disease severity. However, results sug-
gest that this did not translate into increasing costs associated
with resource use and productivity loss. This is contrary to find-
ings of previous analyses [15]. It is possible that the reason for
this outcome is that women in Latin American countries are
both less likely to present for costly treatment and less likely to
be absent from work (despite severity of symptoms) then their
Organisation for Economic Co-operation and Development
counterparts. Presenteeism and affect on daily activities are
reported consistently across the datasets and show a clear re-
lationship with increasing severity as measured by DRSP score.
It would be interesting to explore the reasons for the lack of a
stable relationship between more expensive resources used and
DRSP category to more fully understand if region-specific differ-
ence in health care availability drives the differences between this
and the Organisation for Economic Co-operation and Develop-
ment analysis. Despite this, the estimated cost burden associated
with womenwithmoderate/severe PMD or PMDDwas found to be
highwith themean annual burden estimated in the region of 1500
BRL. Further quantification of the monetary effects of PMDD and
research into potential geographical interactions is needed to bet-
ter understand the burden of moderate to severe PMS and PMDD.
The dataset reported here has a wide applicability and the ap-
proach described could be used to generate such evidence for
other countries.
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